Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
CONMED Corporation manufactures and distributes surgical devices and equipment for orthopedic and general surgery procedures, with particular strength in arthroscopy, powered surgical instruments, and patient monitoring systems. The company operates globally with approximately 60% of revenue from the US market, serving hospitals and ambulatory surgical centers through a direct sales force and distributor network. Stock performance is driven by elective surgery volumes, new product adoption rates in sports medicine and orthopedics, and operating margin expansion through manufacturing efficiency.
CONMED generates revenue through capital equipment sales (visualization systems, powered instruments) and high-margin recurring sales of single-use devices and disposables. The company benefits from razor-razorblade economics where installed capital equipment creates annuity-like consumable revenue streams. Pricing power derives from surgeon preference for specific instruments, regulatory barriers to entry (510(k) clearances, quality certifications), and switching costs once hospitals standardize on CONMED platforms. Direct sales force provides clinical training and procedural support, creating sticky customer relationships. Gross margins of 54% reflect mix of capital equipment (lower margin) and disposables (higher margin), with operating leverage potential as fixed R&D and SG&A costs spread over growing revenue base.
Elective orthopedic surgery volumes, particularly arthroscopy and sports medicine procedures which drive high-margin disposable sales
New product launch success rates and FDA clearance timelines for next-generation instruments and visualization systems
Hospital capital equipment spending budgets and ambulatory surgical center expansion trends
Operating margin trajectory and ability to leverage fixed cost base as revenue grows
Competitive positioning against larger rivals (Stryker, Arthrex, Smith+Nephew) in key product categories
Healthcare reimbursement pressure from CMS and private payers reducing procedure volumes or forcing price concessions on medical devices
Consolidation among hospital systems and group purchasing organizations (GPOs) increasing buyer negotiating power and compressing device pricing
Regulatory intensification including FDA scrutiny on device safety, EU Medical Device Regulation compliance costs, and potential device tax reinstatement
Shift toward value-based care models and bundled payments reducing hospital willingness to pay premium prices for differentiated devices
Market share erosion to larger competitors (Stryker, Arthrex, Smith+Nephew) with broader product portfolios, larger R&D budgets, and stronger surgeon relationships
Technological disruption from robotic surgery platforms (Intuitive Surgical, Stryker Mako) potentially commoditizing traditional arthroscopy instruments
Private equity-backed competitors (e.g., Arthrex) with patient capital and aggressive pricing strategies in sports medicine segment
Debt burden of $1.1B (0.83 D/E) creates refinancing risk if credit markets tighten or operating performance deteriorates, particularly given -64.5% net income decline
Sharp net income decline (-64.5% YoY) and compressed margins (3.4% net margin) suggest operational stress or one-time charges that could pressure covenant compliance
Working capital management risk given medical device inventory obsolescence potential and hospital payment term extensions during economic stress
moderate - Elective orthopedic procedures (60-65% of revenue) are deferrable during economic downturns as patients delay non-urgent surgeries due to employment concerns, insurance coverage changes, or reduced discretionary healthcare spending. However, trauma and emergency procedures provide revenue stability. Hospital capital equipment budgets are procyclical, contracting during recessions when healthcare systems face margin pressure. Ambulatory surgical center growth, a key end-market, correlates with consumer confidence and employment levels since many procedures are cash-pay or high-deductible.
Rising interest rates create moderate headwinds through multiple channels: (1) higher borrowing costs for hospitals and ASCs reduce capital equipment budgets, (2) increased debt service costs on CONMED's $1.1B debt load (0.83 D/E ratio) compress net margins, (3) valuation multiple compression as medical device stocks typically trade on forward P/E and rising discount rates reduce present value of future earnings. However, CONMED's 11.4% FCF yield provides cushion. Lower rates are modestly positive by improving hospital financial flexibility and reducing CONMED's interest expense.
Moderate exposure through hospital and ASC customer financial health. Tightening credit conditions can delay hospital capital equipment purchases and strain ASC expansion financing. CONMED's own balance sheet shows manageable leverage (0.83 D/E, 2.14 current ratio) but refinancing risk exists if credit spreads widen significantly. Customer payment terms and receivables quality deteriorate during credit stress periods.
value - Trading at 1.0x P/S and 1.3x P/B with 11.4% FCF yield suggests deep value orientation despite operational challenges. The -31.8% one-year return and compressed margins attract contrarian investors betting on turnaround execution, margin recovery, or M&A potential. Not a growth stock given 5.2% revenue growth and mature market position. Dividend investors unlikely given need to prioritize debt reduction and reinvestment.
moderate-to-high - Small-cap medical device stocks ($1.3B market cap) exhibit elevated volatility due to limited float, concentrated institutional ownership, and binary outcomes from product launches or FDA decisions. Recent 6-month decline of -19.8% demonstrates downside volatility. Quarterly earnings can move stock significantly given operational leverage and investor focus on margin trajectory. Beta likely 1.2-1.4x relative to broader market.
